The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients

N Bhala; J M Coleman; C R Radstone; J M Horsman; Jacob George; B W Hancock; M Q Hatton; R E Coleman

doi:10.1016/S0936-6555(03)00166-3

The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients

N Bhala, J M Coleman, C R Radstone, J M Horsman, Jacob George, B W Hancock, M Q Hatton, R E Coleman

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

The survival of germ-cell tumours (GCT) was transformed after the introduction of cisplatin-based therapy. Previous trials have indicated BEP (bleomycin, etoposide and cisplatin) as the optimum treatment, although some centres including our own advocate the use of the alternating regimen POMB-ACE (cisplatin, vincristine, methotrexate, bleomycin and dactinomycin, cyclophosphamide and etoposide) for men with intermediate or poor prognosis disease. We analysed the survival and management of GCT patients treated at a specialist cancer centre in relation to internationally recognised prognostic groupings.

Original language	English
Pages (from-to)	40-47
Number of pages	8
Journal	Clinical Oncology
Volume	16
Issue number	1
DOIs	https://doi.org/10.1016/S0936-6555(03)00166-3
Publication status	Published - 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0936-6555(03)00166-3

Embargoed Document

NSGCT paper
Final published version, 139 KB
Embargo ends: 31/12/99

Cite this

@article{b4438a72d80a44579fa228c3a2f8486f,

title = "The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients",

abstract = "The survival of germ-cell tumours (GCT) was transformed after the introduction of cisplatin-based therapy. Previous trials have indicated BEP (bleomycin, etoposide and cisplatin) as the optimum treatment, although some centres including our own advocate the use of the alternating regimen POMB-ACE (cisplatin, vincristine, methotrexate, bleomycin and dactinomycin, cyclophosphamide and etoposide) for men with intermediate or poor prognosis disease. We analysed the survival and management of GCT patients treated at a specialist cancer centre in relation to internationally recognised prognostic groupings.",

author = "N Bhala and Coleman, {J M} and Radstone, {C R} and Horsman, {J M} and Jacob George and Hancock, {B W} and Hatton, {M Q} and Coleman, {R E}",

year = "2004",

doi = "10.1016/S0936-6555(03)00166-3",

language = "English",

volume = "16",

pages = "40--47",

journal = "Clinical Oncology",

issn = "0936-6555",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - The management and survival of patients with advanced germ-cell tumours

T2 - improving outcome in intermediate and poor prognosis patients

AU - Bhala, N

AU - Coleman, J M

AU - Radstone, C R

AU - Horsman, J M

AU - George, Jacob

AU - Hancock, B W

AU - Hatton, M Q

AU - Coleman, R E

PY - 2004

Y1 - 2004

N2 - The survival of germ-cell tumours (GCT) was transformed after the introduction of cisplatin-based therapy. Previous trials have indicated BEP (bleomycin, etoposide and cisplatin) as the optimum treatment, although some centres including our own advocate the use of the alternating regimen POMB-ACE (cisplatin, vincristine, methotrexate, bleomycin and dactinomycin, cyclophosphamide and etoposide) for men with intermediate or poor prognosis disease. We analysed the survival and management of GCT patients treated at a specialist cancer centre in relation to internationally recognised prognostic groupings.

AB - The survival of germ-cell tumours (GCT) was transformed after the introduction of cisplatin-based therapy. Previous trials have indicated BEP (bleomycin, etoposide and cisplatin) as the optimum treatment, although some centres including our own advocate the use of the alternating regimen POMB-ACE (cisplatin, vincristine, methotrexate, bleomycin and dactinomycin, cyclophosphamide and etoposide) for men with intermediate or poor prognosis disease. We analysed the survival and management of GCT patients treated at a specialist cancer centre in relation to internationally recognised prognostic groupings.

U2 - 10.1016/S0936-6555(03)00166-3

DO - 10.1016/S0936-6555(03)00166-3

M3 - Article

C2 - 14768754

SN - 0936-6555

VL - 16

SP - 40

EP - 47

JO - Clinical Oncology

JF - Clinical Oncology

IS - 1

ER -

The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients

Abstract

UN SDGs

Access to Document

Embargoed Document

Fingerprint

Cite this